Literature DB >> 9136942

Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen.

U Schneider1, A van Lessen, D Huhn, S Serke.   

Abstract

The purpose of this study was to optimize the flow cytometric determination of circulating normal and malignant plasma cells (PC). We investigated peripheral blood (PB) samples of 65 patients with multiple myeloma or monoclonal gammopathy of unknown significance and 47 control subjects using CD38, CD45, B-B4, CD56, VLA-4, VLA-5 and CD19 monoclonal antibodies (MoAbs). Mono- or polyclonality was determined by staining of intracellular kappa and lambda light chains. Two subpopulations of PBPC were distinguished by differential expression of CD45. CD45 positive (CD45+) PC showed a more immature morphology and were detected in all groups. They were polyclonal in the control subjects and either poly- or monoclonal in the myeloma patients. In contrast, CD45 negative (CD45-) PBPC only occurred in myeloma patients and were consistently monoclonal, their presence being significantly associated with high disease activity (P < 0.001). Although detection of CD45- PBPC using CD38 or B-B4 MoAbs lead to similar results. CD45+ PBPC often were recognized to a lesser extent by B-B4 than by CD38 MoAbs. In conclusion, normal and malignant circulating PC can reliably be identified using CD38 and CD45 MoAbs. CD45 expression separates PBPC into two subsets of which the CD45- one only occurs in myeloma patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9136942     DOI: 10.1046/j.1365-2141.1997.d01-2115.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  CD52 is not a promising immunotherapy target for most patients with multiple myeloma.

Authors:  Jörg Westermann; Georg Maschmeyer; Antje van Lessen; Bernd Dörken; Antonio Pezzutto
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

2.  A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.

Authors:  Zhong Chen; Bonnie Issa; Shiang Huang; Emily Aston; Jia Xu; Margaret Yu; Arthur R Brothman; Martha Glenn
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

3.  Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry.

Authors:  Henrik E Mei; Michael D Leipold; Axel Ronald Schulz; Cariad Chester; Holden T Maecker
Journal:  J Immunol       Date:  2015-01-21       Impact factor: 5.422

4.  The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Authors:  Wilson I Gonsalves; Michael M Timm; S Vincent Rajkumar; William G Morice; Angela Dispenzieri; Francis K Buadi; Martha Q Lacy; David Dingli; Nelson Leung; Prashant Kapoor; Robert A Kyle; Morie A Gertz; Shaji K Kumar
Journal:  Leuk Res       Date:  2016-03-10       Impact factor: 3.156

5.  Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Leandro S Thiago; Martin Perez-Andres; Ana Balanzategui; Maria E Sarasquete; Bruno Paiva; Maria Jara-Acevedo; Paloma Barcena; Maria Luz Sanchez; Julia Almeida; Marcos González; Jesus F San Miguel; Ramón Garcia-Sanz; Alberto Orfao
Journal:  Haematologica       Date:  2013-07-19       Impact factor: 9.941

Review 6.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

Review 7.  Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.

Authors:  Hideaki Ishikawa; Naohiro Tsuyama; Michio M Kawano
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

8.  Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells.

Authors:  L S Manning; N S Radin
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

9.  Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study.

Authors:  C A Stiller; S Benjamin; R A Cartwright; J V Clough; D W Gorst; M E Kroll; J R Ross; K Wheatley; J A Whittaker; P R Taylor; S J Proctor
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses.

Authors:  Salequl Islam; Nobuaki Shimizu; Sheikh Ariful Hoque; Atsushi Jinno-Oue; Atsushi Tanaka; Hiroo Hoshino
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.